Articles On Botanix Pharmaceuticals (ASX:BOT)

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...

Botanix Pharmaceuticals’ (BOT) Chief Commercial Officer (CCO) is promoted to Chief Operating Officer Dr Howie Mckibbon will retain his responsibilities as CCO but will expand his role to oversee manufacturing, medical affairs and regulatory...

Botanix Pharmaceuticals (BOT) receives positive data from its phase 1b/2 papulopustular rosacea clinical studyThe company reported positive results from the randomised, vehicle-controlled clinical study, which showed the 10 per cent dose re...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced what it describes as positive data from its BTX 1702 Phase 1b/2 papulopustular rosacea clinical study.

ASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge    We’re pretty flat on Wednesday. I am, the benchmark is and so is Australia as a nation and a continent. Luckily Gregor Stronach, my trusty fiend on...

It is hump day, which the ASX 200 benchmark celebrated with a series of increasingly erratic and – dare we say it, erotic – humps on its way to what looks like an unlikely 0.38% win. With another day in the bag, though, it’s time for an eve...

Clinical-stage dermatology Botanix Pharmaceuticals (ASX:BOT) has submitted a New Drug Application to the US FDA for the approval of sofpironium bromide for patients with severe primary axillary hyperhidrosis.

Botanix Pharmaceuticals (BOT) submits a new drug application (NDA) to the US FDA for the use of its sofpironium bromide gel for patients with severe primary axillary hyperhidrosisThe company says it is targeting FDA approval for the fourth...

Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has closed the first tranche of its up to $7.5 million placement to new and existing institutional and sophisticated investors for the placement of up to 113,636,364 ful...

Botanix Pharmaceuticals (BOT) is tapping investors for $7.5 million via a share placementThe company will issue more than 113 million shares to private investors at 6.6 cents to raise the fundsBotanix says it will use the money to fund the...

Small caps burn rest of field. Again. Up 1.8% ASX 200 dips. Again DM1 jumps 75% over two sessions   The ASX Emerging Companies (XEC) index has climbed more than 1.8% higher on Wednesday while its erstwhile brethren which measures the favo...

Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for $5 million to take its Sofpironium Bromide product into sales in the United States. 

Botanix Pharmaceuticals (BOT) accelerates the submission of a New Drug Approval (NDA) for its Sofpironium Bromide gel to be ready to file in Q3 2022 To coincide with the acceleration, Botanix has ramped up its commercial launch activities...

Botanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm’s Technegas is used ahead of competitor products in Covid-19 diagnosis Clinical dermatology company, Botanix Pharma (A...

Clinical dermatology company Botanix Pharmaceuticals (ASX: BOT) is preparing to submit a new drug application (NDA) for novel asset Sofpironium Bromide gel 15% for the treatment of excessive underarm sweating. The application will go to the...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the timing of the submission of the NDA for Sofpironium Bromide has been accelerated.

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Botanix Pharmaceuticals (ASX: BOT) has provided the market with an update on its progress in transforming into a commercial-stage dermatology company following the acquisition of its latest asset, Sofpironium Bromide. The dermatology compan...

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

Actor and cannabis farmer Jim Belushi is headlining the Grow Up Conference and Expo next month Franchise Global Health has established the first legal seedbank in Denmark Botanix nabs FDA Qualified Infection Disease Product designation for...

Botanix Pharmaceuticals (ASX:BOT) has announced the acquisition of a novel dermatology asset known as Sofpironium Bromide gel.

Botanix Pharmaceuticals (BOT) acquires Sofpironium Bromide gel from NASDAQ listed company Brickell Biotech Developed by Brickell, the gel treats primary axillary hyperhidrosis, which causes excessive underarm sweating Through the takeover,...

Shares in Perth dermatology company Botanix Pharmaceuticals have surged after it announced the acquisition of a new drug that will help treat a medical condition which causes excessive underarm sweating.

Botanix Pharmaceuticals (ASX: BOT) has acquired novel dermatology asset Sofpironium Bromide gel 15% for the treatment of primary axillary (underarm) hyperhidrosis, a medical condition which results in excessive underarm sweating. The acquis...

The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The...

Botanix Pharmaceuticals (BOT) is granted Qualified Infectious Disease Product (QIDP) status for its investigational antibacterial product The new status covers usage of the treatment for the “reduction of risk of S. aureus bloodstream i...

ASX to rise after falling for the last three days LNG price surges after Russian cuts off supply to two EU countries Aussie bond market is pricing in a 20bp rate hike in Mayy ASX to rise, LNG prices jump 23% After falling for the last thr...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has confirmed upcoming presentations of data related to its antimicrobial synthetic cannabidiol program BTX 1801.

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

ShareCafeBotanix Pharmaceuticals (ASX: BOT) – Webinar Presentation Matt Callahan – Executive Director – Botanix Pharmaceuticals is a clinical stage dermatology company developing treatments for common skin diseases and infections. Botanix...

ShareCafeWebinar Recap – BOT, TZL & SLH Catch up on the full webinar with presentations from Botanix Pharmaceuticals (ASX: BOT), TZ Limited (ASX: TZL) & Silk Logistics (ASX: SLH) Webinar Recap – BOT, TZL & SLHCompany News

Botanix Pharmaceuticals (BOT) shares its half yearly report and highlights its dermatology program advancements The company incurred a net loss after income tax of $6,508,794 because of the continued advancement of its dermatology and anti...

Botanix Pharmaceuticals (BOT) has continued progressing multiple clinical programs over the September quarter The healthcare stock began its atopic dermatitis study trialling the BTX 1204A formula of synthetic CBD in up to 45 dogs before i...

FNArena will be updating Special Editions of this Report in September dedicated to the August Reporting Season. An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to...

Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont...

Australia has the potential to become the international gold standard for production of medicinal marijuana and multiple ASX-listed companies are seeking to benefit. -Manufacturing of medicinal cannabis products has been legal in Australia...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its latest quarterly report. The cannabinoid-focused pharmaceutical dermatology company’s quarter seemed to be a good one, but the market has reac...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price was a very strong performer on Friday. The clinical stage synthetic cannabinoid company’s shares ended the day a massive 20% higher at 7.8 cents. However, despite this strong gain, the...

Summary ASX-listed digital health company ResApp Health has recruited the first participant in its US-based trial to assess the link between cough and COVID-19. Botanix Pharmaceuticals revealed encouraging results from the BTX 1204A Pi...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

ASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning both given updates on their antimicrobial drug candidates as interest heats up on weapons to combat so-called “superbugs”. Recce said its s...

Summary Medicinal cannabis player Botanix Pharmaceuticals Limited has provided a clinical development update of the BTX 1801 antimicrobial platform. Botanix’s BTX 1801 was safe, well-tolerated, clinically effective in the Phase 2a stud...

Australian clinical dermatology and antimicrobial company Botanix Pharmaceuticals (ASX:BOT) has released a clinical development update of its antimicrobial platform with the identification of a potential new indication.

Summary Digital health behemoth ResMed has released its quarterly results for the March 2021 quarter reporting flat sales. The Company witnessed lower device sales and decreased demand for its ventilators due to COVID-19. However, str...

Botanix Pharmaceuticals (ASX:BOT) says research on the antimicrobial potential of CBD has been supported by the publication of research data from a leading South American academic group in the online journal BioRxiv.